Abbott Laboratories $ABT Stock Position Reduced by DRW Securities LLC

Key Points

• DRW Securities LLC reduced its stake in Abbott Laboratories by 64.7%, selling 4,954 shares, leaving it with 2,700 shares valued at $358,000.
• Abbott Laboratories reported earnings of $1.26 EPS for the last quarter, exceeding revenue estimates of $11.01 billion with actual revenue of $11.14 billion.
• The company declared a quarterly dividend of $0.59 per share, indicating an annual dividend yield of 1.8% and a payout ratio of 29.57%.

DRW Securities LLC trimmed its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 64.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,700 shares of the healthcare product maker's stock after selling 4,954 shares during the quarter. DRW Securities LLC's holdings in Abbott Laboratories were worth $358,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Hughes Financial Services LLC purchased a new position in Abbott Laboratories in the 1st quarter valued at about $27,000. Abound Financial LLC purchased a new position in shares of Abbott Laboratories during the first quarter valued at approximately $28,000. Elequin Capital LP acquired a new stake in Abbott Laboratories during the first quarter worth approximately $30,000. Wormser Freres Gestion purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $32,000. Finally, JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter valued at $32,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.1%

ABT stock traded up $0.11 during midday trading on Friday, reaching $132.92. 3,286,796 shares of the company's stock traded hands, compared to its average volume of 5,000,069. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The business has a 50-day moving average price of $130.68 and a two-hundred day moving average price of $131.38. The company has a market capitalization of $231.33 billion, a P/E ratio of 16.66, a PEG ratio of 2.52 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The business had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, August 15th. Stockholders of record on Tuesday, July 15th were given a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's dividend payout ratio is presently 29.57%.

Analysts Set New Price Targets

A number of brokerages have recently commented on ABT. BTIG Research lowered their price objective on Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, July 18th. Wells Fargo & Company decreased their price target on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research note on Friday, July 18th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price objective for the company from $143.00 to $145.00 in a research note on Friday, July 18th. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a report on Thursday, July 17th. Finally, Leerink Partnrs upgraded shares of Abbott Laboratories to a "hold" rating in a report on Monday, June 16th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has an average rating of "Moderate Buy" and an average target price of $144.47.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.46% of the company's stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.